ASP Isotopes Inc.

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

ASP Isotopes Inc. trades at $3.8, between stages. That is −40.5% against its own 200-day average. It sits at 0% of a 52-week range of $4 to $11. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (3 weeks and counting).

Today the stock is between stages. At $3.8 it trades −40.5% versus its 200-day average and sits at 0% of its 52-week range ($4–$11).

Against the market, two honest reads. Cumulative: over the last 1.0 years the stock moved −50% while the S&P 500 moved +19% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-07-10) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: how the P/E reads against its own history.

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

P/E does not price ASP Isotopes Inc. — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values ASP Isotopes Inc. at 20.0× its FY25 revenue of $0.1 B.

With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

ASP Isotopes Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

44.2/100 — rank 15 of 15 in Chemicals · 50% evidence confidence · provisional, ranked below fully-evidenced peers

ASP Isotopes Inc. scores 44.2 out of 100 against the 15 companies it is compared with in Chemicals, ranking 15. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 25.8 + 5.4 + 10 + 3 = 44.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

ASP Isotopes Inc. reported $0.0 B of revenue in the Mar 26 quarter. The last full year, FY25, came in at $0.1 B. The last four reported quarters add to $0.1 B. A multi-year compound rate is not shown because the annual history behind it is too short to compute one honestly.

ASP Isotopes Inc. reported $0.0 B of revenue in the Mar 26 quarter. The last full year, FY25, came in at $0.1 B. The last four reported quarters add to $0.1 B. A multi-year compound rate is not shown because the annual history behind it is too short to compute one honestly.

FY25 revenue came in at $0.1 B (+400.0% on the year). The latest quarter (Mar 26) printed $0.0 B, null year on year.

→ Revenue slipped — did margins hold as it scaled? Next: −200.0% this quarter (null pp YoY).

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

ASP Isotopes Inc.'s operating margin is −200.0% in the Mar 26 quarter.

ASP Isotopes Inc.'s operating margin is −200.0% in the Mar 26 quarter.

The latest quarter's operating margin is −200.0%, null pp against the same quarter a year ago. Across 2 fiscal years the operating margin has ranged −300.0%–−120.0%.

Why: the numbers show the operating margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.

→ Margins slipped — did that reach the bottom line? Next: profit null in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

ASP Isotopes Inc. posted a net loss of $0.03 B in the Mar 26 quarter. That quarter carries a one-off item larger than its own revenue, so the year-on-year figure is an artefact rather than a trading result. The full FY25 year was a loss of $0.2 B. That loss is 300.0% of the quarter's revenue.

ASP Isotopes Inc. posted a net loss of $0.03 B in the Mar 26 quarter. That quarter carries a one-off item larger than its own revenue, so the year-on-year figure is an artefact rather than a trading result. The full FY25 year was a loss of $0.2 B. That loss is 300.0% of the quarter's revenue.

Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $−0.2 B (null).

🚨 Read this profit with care: at $−0.0 B it is larger than the whole quarter's revenue of $0.0 B — no operating business earns more than it sells, so this is a one-off item (a debt-to-equity conversion, a tax write-back or an asset sale), not money the business earned. The underlying operations are running at −200.0% operating margin; the year-on-year jump and any P/E built on this number are artefacts of the one-off, not a real earnings turn.

→ Profit rose — but did the cash follow?

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

ASP Isotopes Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $−0.0 B of operating cash against $−0.2 B of profit. After $0.0 B of capital spending, $−0.1 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY25: operating cash of $−0.0 B against reported profit of $−0.2 B, leaving free cash of $−0.1 B after $0.0 B of capital spending.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

→ So follow the cash to where it goes. Next: $0.0 B of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

ASP Isotopes Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROE is −103% and the ROIC − WACC spread is −30.9 pp.

Returns on capital ROE is the profit the business earns on the money invested in it — the single best test of whether growth creates value or just size.

An annual ROE ladder is not held for ASP Isotopes Inc..

We do not hold an annual ROE series for ASP Isotopes Inc.. Its filings carry the return lines we would need as blanks rather than numbers, so this page does not estimate one. The revenue, margin, cash-flow and ownership sections are the reads we stand behind.

→ Who owns ASP Isotopes Inc., and are they adding or leaving? Next: short interest is 18.3% of the float.

Dividend

ASP Isotopes Inc. pays no dividend. Across the last 10 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

ASP Isotopes Inc. does not currently pay a dividend. Across the last 10 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

→ No payout to follow. The cash question becomes what the business does with what it earns instead.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Debt-to-equity is 0.88 at the latest reading — modestly levered; a full borrowings history is not in our numbers.

We hold only the latest reading here: a debt-to-equity of 0.88 — a modest level of leverage behind the returns above. A year-by-year borrowings ladder is not in our numbers for this stock, so we say that rather than draw a chart we cannot support.

→ Who owns this, and are they adding or leaving? Next: short interest is 18.3% of the float.

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

18.3% of ASP Isotopes Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 5.6 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 18.3% of the float is sold short, and at typical trading volumes it would take about 5.6 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

ASP Isotopes Inc.: the Z-score reads 1.07. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

🚨 Why it matters: a Z-score of 1.07 is inside the distress zone — the balance sheet is a real risk, not a detail.

The safety line in one sentence: the Z-score reads 1.07.

Frequently asked questions